Marc Talló-Parra
Chief Scientific Officer NoctuRNA Therapeutics
Marc Talló-Parra is the CSO and co-founder of noctuRNA Therapeutics S.L., a spin-off established based on the groundbreaking work from his PhD at the Universitat Pompeu Fabra. His research focused on the interplay between viral infections and circRNAs. This expertise culminated in developing an innovative, circRNA-based therapeutic platform. This technology targets and impairs the formation of aberrant secondary RNA structures critical for disease, demonstrating high efficiency against a range of viruses and genetic disorders.
